Literature DB >> 29863174

Cost-effectiveness in managing skeletal related events in breast cancer: a strategy of less-intense dosing schedule of bone modifying agents.

Sri Harsha Tella1,2, Anuhya Kommalapati2, Ryan K Singhi2.   

Abstract

Entities:  

Year:  2018        PMID： 29863174      PMCID： PMC5983387          DOI： 10.21037/tcr.2018.01.07

Source DB:  PubMed          Journal:  Transl Cancer Res        ISSN： 2218-676X            Impact factor:   1.241


× No keyword cloud information.
  17 in total

1.  Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.

Authors:  Alison Stopeck; Michael Rader; David Henry; Mark Danese; Marc Halperin; Ze Cong; Yi Qian; Roger Dansey; Karen Chung
Journal:  J Med Econ       Date:  2012-03-27       Impact factor: 2.448

Review 2.  Evaluation and management of skeletal disease in cancer care.

Authors:  Anuhya Kommalapati; Sri Harsha Tella; Mary Angelynne Esquivel; Ricardo Correa
Journal:  Crit Rev Oncol Hematol       Date:  2017-09-08       Impact factor: 6.312

3.  Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.

Authors:  Andrew L Himelstein; Jared C Foster; James L Khatcheressian; John D Roberts; Drew K Seisler; Paul J Novotny; Rui Qin; Ronald S Go; Stephen S Grubbs; Tracey O'Connor; Mario R Velasco; Douglas Weckstein; Ann O'Mara; Charles L Loprinzi; Charles L Shapiro
Journal:  JAMA       Date:  2017-01-03       Impact factor: 56.272

4.  Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases.

Authors:  Jipan Xie; Melissa Diener; Rachael Sorg; Eric Q Wu; Madhav Namjoshi
Journal:  Clin Breast Cancer       Date:  2012-06-12       Impact factor: 3.225

Review 5.  Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates.

Authors:  D B Kimmel
Journal:  J Dent Res       Date:  2007-11       Impact factor: 6.116

6.  American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel.

Authors:  B E Hillner; J N Ingle; J R Berenson; N A Janjan; K S Albain; A Lipton; G Yee; J S Biermann; R T Chlebowski; D G Pfister
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

7.  Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer.

Authors:  Sonya J Snedecor; John A Carter; Satyin Kaura; Marc F Botteman
Journal:  Clin Ther       Date:  2012-05-11       Impact factor: 3.393

8.  Cost per patient and potential budget implications of denosumab compared with zoledronic acid in adults with bone metastases from solid tumours who are at risk of skeletal-related events: an analysis for Austria, Sweden and Switzerland.

Authors:  Mickael Lothgren; Erna Ribnicsek; Louise Schmidt; Wolfgang Habacher; Jonas Lundkvist; Alena M Pfeil; Irina Biteeva; Polina Vrouchou; Andrea Bracco
Journal:  Eur J Hosp Pharm       Date:  2013-02-21

9.  Bone-targeted agent use for bone metastases from breast cancer and prostate cancer: A patient survey.

Authors:  Brian Hutton; Patricia Morretto; Urban Emmenegger; Sasha Mazzarello; Iryna Kuchuk; Christina L Addison; Freya Crawley; Christine Canil; Shawn Malone; Scott Berry; Dean Fergusson; Mark Clemons
Journal:  J Bone Oncol       Date:  2013-06-21       Impact factor: 4.072

10.  De-escalated administration of bone-targeted agents in patients with breast and prostate cancer-A survey of Canadian oncologists.

Authors:  Brian Hutton; Christina Addison; Sasha Mazzarello; Anil A Joy; Nathaniel Bouganim; Dean Fergusson; Mark Clemons
Journal:  J Bone Oncol       Date:  2013-04-15       Impact factor: 4.072
View more
  1 in total

1.  Construction of differentially expressed Her-2 related lncRNA-mRNA-miRNA ceRNA network in Her-2 positive breast cancer.

Authors:  Xiaochen Jia; Wenjing Meng; Lu Zhang; Yongsheng Jia; Yehui Shi; Zhongsheng Tong
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.